Table 1 Demographic information and KAP scores.
From: Knowledge, attitude, and practice toward antiviral treatment of chronic hepatitis B among patients
Variables | N (%) | Knowledge score | Attitude score | Practice score | |||
|---|---|---|---|---|---|---|---|
Mean ± SD | P | Mean ± SD | P | Mean ± SD | P | ||
Total | 457 | 9.7 ± 4.6 | 24.0 ± 3.3 | 38.9 ± 6.6 | |||
Gender | < 0.001 | 0.676 | 0.010 | ||||
Male | 312 (68.3) | 10.3 ± 4.6 | 24.0 ± 3.3 | 39.4 ± 6.3 | |||
Female | 145 (31.7) | 8.5 ± 4.5 | 24.1 ± 3.4 | 37.7 ± 6.9 | |||
Age | 48.0 ± 12.2 | ||||||
Education | < 0.001 | < 0.001 | 0.007 | ||||
High school and below | 268 (58.6) | 9.0 ± 4.7 | 23.3 ± 3.1 | 38.2 ± 6.8 | |||
Undergraduate and above | 189 (41.4) | 10.7 ± 4.4 | 24.9 ± 3.3 | 39.8 ± 6.2 | |||
Household income | < 0.001 | < 0.001 | 0.045 | ||||
< 5000 | 254 (55.6) | 8.8 ± 4.5 | 23.3 ± 3.0 | 38.2 ± 7.0 | |||
5000-10,000 | 139 (30.4) | 10.6 ± 4.6 | 24.6 ± 3.5 | 39.3 ± 5.9 | |||
> 10,000 | 64 (14.0) | 11.5 ± 4.3 | 25.3 ± 3.1 | 40.3 ± 6.0 | |||
Drinking | 0.202 | 0.003 | 0.022 | ||||
No | 393 (86.0) | 9.6 ± 4.7 | 24.2 ± 3.2 | 39.1 ± 6.6 | |||
Yes | 64 (14.0) | 10.4 ± 4.3 | 22.9 ± 3.8 | 37.1 ± 6.1 | |||
Smoking | 0.663 | 0.072 | 0.915 | ||||
Never | 252 (55.1) | 9.7 ± 4.8 | 24.3 ± 3.3 | 39.0 ± 6.6 | |||
Often | 97 (21.2) | 9.4 ± 4.7 | 23.8 ± 3.0 | 38.9 ± 6.3 | |||
Continue | 108 (23.6) | 10.0 ± 4.3 | 23.5 ± 3.5 | 38.6 ± 6.7 | |||
Type of medical insurance | < 0.001 | 0.006 | 0.008 | ||||
Basic medical insurance | 323 (70.7) | 10.4 ± 4.5 | 24.3 ± 3.4 | 39.5 ± 6.4 | |||
New cooperative medical insurance | 113 (24.7) | 8.0 ± 4.6 | 23.3 ± 2.6 | 37.3 ± 6.8 | |||
Commercial medical insurance/No medical insurance | 21 (4.6) | 8.5 ± 4.7 | 23.1 ± 3.6 | 37.6 ± 7.1 | |||
Family history | < 0.001 | < 0.001 | < 0.001 | ||||
Yes | 170 (37.2) | 9.9 ± 4.5 | 24.8 ± 3.2 | 40.5 ± 6.4 | |||
No | 237 (51.9) | 10.1 ± 4.6 | 23.7 ± 3.2 | 38.3 ± 6.4 | |||
Unclear | 50 (10.9) | 7.1 ± 4.2 | 22.6 ± 3.3 | 35.6 ± 6.2 | |||
Hepatitis B stage | 0.063 | < 0.001 | 0.028 | ||||
Chronic | 279 (61.1) | 10.0 ± 4.8 | 24.7 ± 3.1 | 39.5 ± 6.5 | |||
Cirrhosis | 114 (24.9) | 9.4 ± 4.5 | 22.8 ± 3.0 | 37.3 ± 6.4 | |||
Liver cancer | 21 (4.6) | 10.4 ± 4.0 | 21.9 ± 5.1 | 38.4 ± 6.5 | |||
Carrier | 43 (9.4) | 8.1 ± 4.1 | 23.9 ± 2.8 | 38.8 ± 7.2 | |||
Disease duration | 0.173 | 0.417 | 0.389 | ||||
≤ 10 years | 171 (37.4) | 9.3 ± 4.9 | 24.2 ± 3.1 | 38.5 ± 6.8 | |||
> 10 years | 286 (62.6) | 9.9 ± 4.5 | 23.9 ± 3.4 | 39.1 ± 6.4 | |||
Treatment period | 0.002 | 0.318 | 0.148 | ||||
< 1 year | 50 (10.9) | 8.0 ± 5.1 | 24.1 ± 2.7 | 39.2 ± 7.1 | |||
1–5 years | 204 (44.6) | 9.4 ± 4.5 | 24.2 ± 3.4 | 38.1 ± 6.7 | |||
6–10 years | 102 (22.3) | 10.0 ± 4.2 | 24.1 ± 2.9 | 39.6 ± 6.4 | |||
> 10 years | 101 (22.1) | 10.9 ± 4.7 | 23.5 ± 3.6 | 39.5 ± 6.1 | |||
Antiviral treatment variation | 0.038 | < 0.001 | 0.371 | ||||
Never | 265 (58.0) | 9.4 ± 4.7 | 24.4 ± 3.2 | 39.1 ± 6.7 | |||
< 3 times | 137 (30.0) | 9.8 ± 4.4 | 23.7 ± 3.0 | 38.7 ± 6.6 | |||
> 3 times | 55 (12.0) | 11.1 ± 4.5 | 22.7 ± 4.0 | 37.8 ± 5.6 | |||
